Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss treatments vary greatly in effectiveness and timelines, with no guaranteed results. Common treatments mentioned include finasteride, minoxidil, and RU58841.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Switching from finasteride to dutasteride led to hair density loss, prompting consideration of returning to finasteride. Consistency with dutasteride and adding RU58841 did not prevent the loss, and users suggest giving dutasteride more time or consulting a dermatologist.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

A 23-year-old has been using finasteride every other day and topical minoxidil daily for five months to address hair thinning, with plans to resume dermarolling. They experienced minimal shedding and are considering switching to daily finasteride for better results.

A 27-year-old male shared his positive experience using finasteride and minoxidil for hair regrowth over a year, noting initial shedding but no significant side effects. He emphasized the effectiveness of combining these treatments and advised others to consult doctors and be patient with the process.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.

Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hair follicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The user experienced significant hair shedding in areas not covered by a previous hair transplant, despite using finasteride and minoxidil for two years. They are advised to consult a dermatologist for professional guidance, as the shedding could be due to various reversible causes.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

A user shared their hair loss treatment progress, using 5% Minoxidil twice daily, 0.5 mg Finasteride daily, and a 1.5 mm dermaroller weekly. They started with a 1 mm dermaroller in May 2022.

RU58841 is considered an effective topical anti-androgen for hair loss, often used with minoxidil. Concerns exist about its purity and sourcing since it's not FDA-approved.

The user has been using finasteride and minoxidil for 4 years and switched to dutasteride and minoxidil 6 months ago, but is concerned about lack of progress and hair loss. They have not experienced side effects and are considering other options like blood tests and dosage adjustments.

The user experienced significant hair regrowth and improved hair density after four months using finasteride, minoxidil, and microneedling, avoiding the need for a hair transplant. They plan to continue their current routine due to positive results and are not considering switching to dutasteride.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

The user has been using finasteride for 13 months and minoxidil for 2.5 years but continues to experience significant hair loss. Suggestions include switching to dutasteride and increasing the oral minoxidil dose to 5mg, while also considering lifestyle changes like diet and stress management.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Switching from topical to oral minoxidil, specifically using split dosing, led to significant hair regrowth and reduced side effects for the user. The combination of oral minoxidil and finasteride proved more effective than previous topical treatments.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

A 20-year-old is using oral minoxidil, finasteride, and a dermastamp to address hair loss but is concerned about continued thinning and lack of visible regrowth after six months. They are questioning if diet, vitamin deficiencies, or dosage adjustments could impact progress.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

Switching to Dutasteride worsened hair condition, causing shedding and inflammation. The user will continue Dutasteride until 18 months before possibly switching back to Finasteride, while using oral Minoxidil.